This Company Will Produce Pharma Firm Cadila's 3-Dose COVID-19 Vaccine 'ZyCov-D'

Cadila, which is expected to begin supplying its vaccine from next month, aims to make 100 million to 120 million doses of ZyCoV-D a year.

Drugmaker Shilpa Medicare Limited said on Friday it had agreed to produce Cadila Healthcare Ltd's three-dose COVID-19 vaccine.

The country's health authorities had given emergency approval in August for Cadila's vaccine, the world's first COVID-19 DNA shot, in adults and children aged 12 years and above.

Cadila, which is expected to begin supplying its vaccine from next month, aims to make 100 million to 120 million doses of ZyCoV-D a year.

While India's vaccination programme aims to inoculate all eligible adults by December, the country also expects to resume exports to meet its commitments under the global COVAX initiative from October to December.